Full View

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

N Tsuchiya, A Hosono, T Yoshikawa, K Shoda… - …, 2018 - Taylor & Francis
The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer
immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized …
被引用次数：48 相关文章

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.

N Tsuchiya, A Hosono, T Yoshikawa, K Shoda… - …, 2017 - europepmc.org
The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer
immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized …

[引用][C] Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

N Tsuchiya, A Hosono, T Yoshikawa, K Shoda… - …, 2017 - cir.nii.ac.jp
Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory
pediatric solid tumors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
[HTML] nih.gov

[HTML][HTML] Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

N Tsuchiya, A Hosono, T Yoshikawa, K Shoda… - …, 2018 - ncbi.nlm.nih.gov
The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer
immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized …

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

N Tsuchiya, A Hosono, T Yoshikawa… - …, 2018 - keio.elsevierpure.com
The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer
immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized …

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

N Tsuchiya, A Hosono, T Yoshikawa… - …, 2017 - pubmed.ncbi.nlm.nih.gov
The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer
immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized …

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

N Tsuchiya, A Hosono, T Yoshikawa… - …, 2018 - kyushu-u.elsevierpure.com
The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer
immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized …

[引用][C] Phase I study of glypican‐3‐derived peptide vaccine therapy for patients with refractory pediatric solid tumors

N Tsuchiya - OncoImmunology, 2017 - cir.nii.ac.jp
Phase I study of glypican‐3‐derived peptide vaccine therapy for patients with refractory
pediatric solid tumors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

N Tsuchiya, A Hosono, T Yoshikawa… - …, 2018 - keio.elsevierpure.com
抄録 The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer
immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized …

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.

N Tsuchiya, A Hosono, T Yoshikawa, K Shoda… - …, 2017 - europepmc.org
The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer
immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized …